PKU HealthCare Corp., Ltd.

The company's predecessor was Southwest Synthetic Pharmaceutical Factory, founded in 1965, and successfully listed on the Shenzhen Stock Exchange in 1997. The company has built a nationwide pharmaceutical sales network covering everything from drug sales, pharmaceutical distribution, hospital collection to supply chain hosting. In the future, the company will strive to build a nationally leading generic pharmaceutical technology enterprise integrating raw materials and formulations, and become a pharmaceutical listed company with an important influence in the Chinese pharmaceutical industry. The company is mainly engaged in R&D, production and sales of chemical preparations, pharmaceutical distribution, and medical services. The company's main products: injectable ceftriaxone, meropenem for injection, cefaminol sodium hydrochloride, clindamycin palmitate granules, buspirone hydrochloride tablets, naphthymidone capsules, celecoxib capsules, dexketoprofen tablets, dexketoprofen capsules, buspirone hydrochloride tablets, olanzapine tablets. Corporate honors: A national technology center, a key Chinese pharmaceutical enterprise, a national innovative pilot enterprise, a key high-tech enterprise of the National Torch Program, etc.